Literature DB >> 10102942

Review article: the potential role of nitric oxide in chronic inflammatory bowel disorders.

A Perner1, J Rask-Madsen.   

Abstract

The aetiology of the chronic inflammatory bowel diseases-ulcerative colitis and Crohn's disease-as well as 'microscopic colitis'-both collagenous (COC) and lymphocytic colitis (LC)-remains unknown. Autoimmune mechanisms, cytokine polymorphism, commensal bacteria, infectious agents and vascular impairment have all been proposed as playing important roles in the pathogenesis of this spectrum of diseases. A variety of proinflammatory mediators, including tumour necrosis factor alpha, interleukin-1beta, interferon gamma, leukotriene B4 and platelet activating factor, promote the adherence of phagocytes to the venular endothelium and extravasation of these cells into the colonic mucosa. In addition to large amounts of nitric oxide (NO), injurious peroxynitrite may be formed in the epithelium by the inducible nitric oxide synthase (iNOS), which is considered to elicit cytotoxicity by the generation of superoxide with reduced L-arginine availability. In active ulcerative colitis, and to a lesser extent in Crohn's disease, a greatly increased production of NO has been demonstrated by indirect and direct measurements. Surprisingly, even higher rates of production have been observed in COC-a condition which is never associated with injurious inflammation. The latter observation favours the notion that NO promotes mucosal integrity. Further evidence for a protective role of NO in chronic inflammatory bowel disorders is provided by the observation of increased susceptibility to the induction of experi mental colitis in 'knock-out' mice deficient in iNOS. Selective inhibitors of iNOS activity, as well as topical L-arginine, may therefore prove beneficial in inflammatory bowel disease by reducing the production of superoxide by iNOS, while only the former option may be expected to reduce diarrhoea in chronic inflammatory bowel disorders. Clearly, further experimental work needs to be done before testing topical L-arginine in human inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102942     DOI: 10.1046/j.1365-2036.1999.00453.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

1.  Collagenous colitis in adult Sri Lankans: experience from the Indian subcontinent.

Authors:  R L Satarasinghe; H R R Fernando; D H Jayamaha; I Samarasinghe; A P De Silva
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

2.  Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions.

Authors:  J S Liu; M L Zhao; C F Brosnan; S C Lee
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

3.  Strictosamide alleviates the inflammation in an acute ulcerative colitis (UC) model.

Authors:  Qinghui Jia; Haihua Zhang; Yongmei Su; Xin Liu; Jiangsong Bai; Wuying Lang; Qiumei Shi; Minshan Feng
Journal:  J Physiol Biochem       Date:  2021-02-17       Impact factor: 4.158

4.  Polymorphisms of the IL-1beta and IL-1beta-inducible genes in ulcerative colitis.

Authors:  Hiroaki Nohara; Yuki Saito; Singo Higaki; Naoko Okayama; Yuichiro Hamanaka; Kiwamu Okita; Yuji Hinoda
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

5.  Suppressive Effect on Lipopolysaccharide-Induced Proinflammatory Mediators by Citrus aurantium L. in Macrophage RAW 264.7 Cells via NF-κB Signal Pathway.

Authors:  Sang-Rim Kang; Dae-Yong Han; Kwang-Il Park; Hyeon-Soo Park; Yong-Bae Cho; Hu-Jang Lee; Won-Sup Lee; Chung Ho Ryu; Yeong Lae Ha; Do Hoon Lee; Jin A Kim; Gon-Sup Kim
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-21       Impact factor: 2.629

6.  Comparative protective effect of hawthorn berry hydroalcoholic extract, atorvastatin, and mesalamine on experimentally induced colitis in rats.

Authors:  Hassan Malekinejad; Vahid Shafie-Irannejad; Rahim Hobbenaghi; Seyed Hamed Tabatabaie; Seyed-Mehdi Moshtaghion
Journal:  J Med Food       Date:  2013-07       Impact factor: 2.786

7.  Cytolethal distending toxin promotes Helicobacter cinaedi-associated typhlocolitis in interleukin-10-deficient mice.

Authors:  Z Shen; Y Feng; A B Rogers; B Rickman; M T Whary; S Xu; K M Clapp; S R Boutin; J G Fox
Journal:  Infect Immun       Date:  2009-03-23       Impact factor: 3.441

8.  Thrombospondin-1 and VEGF in inflammatory bowel disease.

Authors:  Canan Alkim; Damlanur Sakiz; Huseyin Alkim; Ayten Livaoglu; Tulin Kendir; Huseyin Demirsoy; Levent Erdem; Nihat Akbayir; Mehmet Sokmen
Journal:  Libyan J Med       Date:  2012-01-30       Impact factor: 1.657

9.  Increased urinary nitrite, a marker of nitric oxide, in active inflammatory bowel disease.

Authors:  M G Goggins; S A Shah; J Goh; A Cherukuri; D G Weir; D Kelleher; N Mahmud
Journal:  Mediators Inflamm       Date:  2001-04       Impact factor: 4.711

10.  Polymorphisms within inflammatory genes and colorectal cancer.

Authors:  Stefano Landi; Federica Gemignani; Fabio Bottari; Lydie Gioia-Patricola; Elisabet Guino; María Cambray; Sebastiano Biondo; Gabriel Capella; Laura Boldrini; Federico Canzian; Victor Moreno
Journal:  J Negat Results Biomed       Date:  2006-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.